Audentes Therapeutics (BOLD) to be Acquired by Astellas Pharma for $60/share

Go back to Audentes Therapeutics (BOLD) to be Acquired by Astellas Pharma for $60/share

H.C. Wainwright Downgrades Audentes Therapeutics (BOLD) to Neutral Following Acquisition

December 3, 2019 7:15 AM EST

H.C. Wainwright analyst Debjit Chattopadhyay downgraded Audentes Therapeutics (NASDAQ: BOLD) from Buy to Neutral.

For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.

Shares of Audentes Therapeutics closed at $28.61 yesterday.

... More

Mizuho Securities Downgrades Audentes Therapeutics (BOLD) to Neutral Following Acquisition

December 3, 2019 6:53 AM EST

Mizuho Securities analyst Difei Yang downgraded Audentes Therapeutics (NASDAQ: BOLD) from Buy to Neutral with a price target of $60.00.

For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.

Shares of Audentes Therapeutics closed at $28.61 yesterday.

... More

Wedbush Downgrades Audentes Therapeutics (BOLD) to Neutral Following Acquisition

December 3, 2019 6:49 AM EST

Wedbush analyst David Nierengarten downgraded Audentes Therapeutics (NASDAQ: BOLD) from Outperform to Neutral with a price target of $60.00 (from $44.00).

For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.

Shares of Audentes Therapeutics closed at $28.61 yesterday.

... More

Raymond James Downgrades Audentes Therapeutics (BOLD) to Market Perform Following Acquisition

December 3, 2019 6:26 AM EST

Raymond James analyst Steven Seedhouse downgraded Audentes Therapeutics (NASDAQ: BOLD) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.

Shares of Audentes Therapeutics closed at $28.61 yesterday.

... More

BMO Capital Downgrades Audentes Therapeutics (BOLD) to Market Perform Following Acquisition

December 3, 2019 5:07 AM EST

BMO Capital analyst Matthew Luchinitthew Lichini downgraded Audentes Therapeutics (NASDAQ: BOLD) from Outperform to Market Perform with a price target of $60.00 (from $47.00).

For an analyst ratings summary and ratings history on Audentes Therapeutics click... More